GlassScriptPhysician profile
Howard S Taylor
NPI 1336235423
$4,357.21
in general payments reported to CMS, 2019-2025
34 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $280 · 2021: $378 · 2022: $710 · 2023: $756 · 2024: $815 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,016 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.08 |
| Education | $101.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $849.53 | 2019-2025 | Austedo Xr, Austedo Xr |
| Genzyme Corporation | $531.99 | 2019-2023 | |
| Lilly USA, LLC | $430.42 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Pfizer INC. | $271.43 | 2023-2025 | |
| Abbvie INC. | $265.60 | 2021-2025 | Botox, Ubrelvy |
| Alexion Pharmaceuticals, INC. | $256.72 | 2019-2024 | Ultomiris, Soliris |
| Celgene Corporation | $199.49 | 2023-2025 | Zeposia |
| Biogen, INC. | $171.72 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $132.55 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.91 | 2023-2024 | Hyqvia, Gammagard |
| Eisai INC. | $120.67 | 2023-2025 | |
| Ucb, INC. | $105.30 | 2020-2024 | Zilbrysq, Nayzilam |
| Amgen INC. | $88.35 | 2022-2023 | Aimovig |
| Acorda Therapeutics, INC | $85.13 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $82.46 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $77.18 | 2023 | Aptiom |
| W. L. Gore & Associates, INC. | $76.00 | 2021 | |
| Allergan, INC. | $58.61 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $57.92 | 2019 | |
| Merz Pharmaceuticals, LLC | $45.23 | 2023-2024 | Xeomin |
| Kyowa Kirin, INC. | $42.15 | 2019-2024 | Nourianz |
| Csl Behring | $37.59 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $33.29 | 2025 | Zeposia |
| Acadia Pharmaceuticals INC | $26.91 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $24.97 | 2021 | |
| Lundbeck LLC | $24.28 | 2019 | |
| Boston Scientific Corporation | $23.39 | 2024 | |
| Alnylam Pharmaceuticals INC. | $22.74 | 2019 | |
| Ge Healthcare | $21.49 | 2019 | |
| Upsher-Smith Laboratories LLC | $17.43 | 2020 | |
| Avion Pharmaceuticals | $16.50 | 2022 | |
| Vertical Pharmaceuticals, LLC | $15.60 | 2019 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Emd Serono, INC. | $10.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.